Personalization is all the rage these days. Whether we're talking about the business of entertainment, food, or clothing, consumers have more options today than anyone imagined possible a couple of decades ago.

(NASDAQ: MRNA) and its big pharma collaboration partner, Merck (NYSE: MRK), recently posted compelling clinical-trial results that suggest cancer treatments are about to become a lot more personalized too. On Monday, June 5, the partners showed off compelling results for a personalized cancer vaccine that Moderna calls mRNA-4157 and Merck calls V940.

There are a whole lot of ins and outs when it comes to interpreting cancer-trial data. Let's look at the most important details to see if Moderna's a smart stock to buy now.

Continue reading

Source Fool.com